4:46 PM
 | 
Oct 10, 2013
 |  BC Extra  |  Clinical News

Ofatumumab meets in Phase II RRMS trial

Genmab A/S (CSE:GEN) said all doses of subcutaneous ofatumumab met the primary endpoint in the Phase II MIRROR trial to treat relapsing-remitting multiple sclerosis (RRMS). Ofatumumab led to a 65% reduction in the cumulative number of new T1-weighted gadolinium-enhancing brain lesions as measured by...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >